Home
Resources
Publications
Timolol Maleate 0.5% Versus Timolol Maleate in Gel Forming Solution 0.5% (Timolol GFS) in Open Angle Glaucoma in India. Preliminary Safety and Efficacy Study

Timolol Maleate 0.5% Versus Timolol Maleate in Gel Forming Solution 0.5% (Timolol GFS) in Open Angle Glaucoma in India. Preliminary Safety and Efficacy Study

Harsh Kumar, Rajeev Sudan, Harinder S Sethi, Parul Sony

Indian J Ophthalmol. 2002 Mar;50(1):21-3.

PMID: 12090082

Abstract:

Purpose:
To compare the efficacy and safety profile of Timolol maleate 0.5% versus Timolol gel forming solution (GFS) 0.5% in open angle glaucoma in Indian eyes.
Methods:
In a prospective crossover study 52 patients of open angle glaucoma, well controlled intraocular pressure (IOP) on 0.5% timolol maleate solution were switched over to timolol GFS once a day, after a washout period of one month. A diurnal IOP measurement was done after 6 weeks and compared with patients on timolol maleate 0.5% twice a day. In addition, side effects reported or observed were compared.
Results:
Statistically significant difference was not observed in ocular hypotensive effect of the two treatment. The side-effects in both the treatment groups were similar except for higher incidence of blurring of vision in patients on timolol GFS. The compliance was better with timolol GFS, but was not statistically significant.
Conclusion:
The results of this study suggest that the more convenient 0.5% timolol in gel forming solution can be offered as an equally efficacious and well-tolerated alternative to twice daily 0.5% timolol solution in open angle glaucoma.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1219806457	Chlorpheniramine-D6 maleate solution		1219806-45-7	Price
AP136765474	(±)-Norpropoxyphene-d5 maleate solution		136765-47-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: